



सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/24/000091

To,

M/s Novo Nordisk India Private Limited,
Nxt Tower-2, Floor 1 & 2, Embassy Manyata Business Park,
Nagavara Village, Kasaba Hobli, Bangalore-560045, India

Sir,

With reference to your application No. GCT/CT04/FF/2024/44329 dated 10-Jul-2024, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease” Protocol No.: NN7535-7807 Version No. 1.0 Protocol Date 18-Apr-2024 with a total of up-to 100 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- 1) **Human biological samples i.e. Human blood (whole), serum, and Plasma related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO.**
- 2) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- 3) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- 4) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- 5) the Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- 6) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- 7) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- 8) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- 9) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- 10) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- 11) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- 12) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- 13) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- 14) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- 15) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- 16) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- 17) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- 18) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- 19) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- 20) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s Novo Nordisk India Private Limited, Nxt Tower-2, Floor 1 & 2, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore-560045** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: NN7535-7807 Version No. 1.0 Protocol Date 18-Apr-2024** in the below mentioned clinical trial sites [As per Annexure].
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Etavopivat 200mg/ Placebo
Therapeutic class:	Oralerythrocyte pyruvate kinase activator
Dosage form:	Tablets
Indications:	Sickle Cell Disease

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1	Nirmal Hospital Pvt. Ltd, Ring Road, Surat, Gujarat –395002, India	Nirmal Hospital Pvt Ltd Ethics Committee Nirmal Hospital Pvt. Ltd, Ring Road, Surat, Gujarat –395002, India ECR/390/Inst/GJ/2013/RR-19	Dr. Dharmesh Vaghasiya
2	Department of General medicine, D Block, Gate no 4, AIIMS Raipur, Tatibandh, Raipur, Chhattisgarh –492099, India	Institute Ethics Committee, AIIMS Raipur, Room no. 2103, 2nd Floor South Wing, Medical College Complex, Gate No. 5, All India Institute of Medical Sciences, Tatibandh, GE Road, Raipur, 492099, Chhattisgarh, India ECR/714/Inst/CT/2015/RR-21	Dr. Pankaj Kumar Kannauje
3	Clinical Study Room, 2nd floor, New Emergency Building, SSG Hospital, Medical College –Baroda, Vadodara –390001, Gujarat, India	IEC Office, 1st floor, New Library Building, Medical College -Baroda, Sayajigunj, Vadodara -390001, Gujarat, India ECR/85/Inst/GJ/2013/RR-24	Dr. Rupal Dosi
4	IMS and SUM Hospital, Department of Haematology, K-8, Kalinganagar, Bhubaneswar, Odisha, 751003, India	Institute of Medical Sciences and SUM Hospital, K-8, Kalinga Nagar, Shampur, Bhubaneswar, 751003-Odisha ECR/627/Inst/OR/2014/RR-20	Dr. Priyanka Samal

5	Department of Haematology, AIIMS, 5th Floor, Porta Cabin, Academic Block, All India Institute of Medical Sciences (AIIMS), New Delhi -110029, India	Institute Ethics Committee All India Institute of Medical Sciences Old OT Block, Room No. 102, AIIMS Hospital Ansari Nagar, South Delhi, New Delhi -110029 India ECR/538/Inst/DL/2014/RR-20	Dr. Tulika Seth
6	Department of Paediatric Haematology-Oncology, Post Graduate Institute of Child Health, Sector 30, Noida, Gautam Budh Nagar, Uttar Pradesh -201303, India	Institutional Ethics Committee Super Speciality Pediatric Hospital & PGTI Post Graduate Institute of Child Health Sector 30, NOIDA, Gautam Budh Nagar, Uttar Pradesh, 201303, INDIA ECR/1320/Inst/UP/2019	Dr. Nita Radhakrishnan
7	Department of General Medicine, JSS Hospital, M G Road, Mysuru -570004, Karnataka, India	Institutional Ethics Committee and JSS medical College and Hospital, Sri Shivarathreeshwara Nagar, Mysuru-570015 ECR/387/Inst/KA/2013/RR-22	Dr. Venkatesh C R
8	Zydus Medical College & Hospital Civil Hospital, Opp. Naheru Baug, Behind Bhagini Samaj, Station Road, Dahod -389151, Gujarat	Zydus Medical College and Hospital Zydus Medical College and Hospital, Dahod Civil Hospital, Opp. Nehru Baug, Station Road Dahod 389151 Dahod Gujarat - 389151 India ECR/1464/Inst/GJ/2020	Dr. Mohitkumar Gajendrabhai Desai
9	Government Medical College, Clinical Research Room, Department of General Medicine, Opposite OP Pharmacy, Kozhikode, Kerala -673008, India	Institutional Ethics Committee, Government Medical College Kozhikode, Room No. 1 & 2, Ground floor, Lecture Theatre Complex, Medical College Campus, Medical College P. O, Calicut-673008, Kerala ECR/395/Inst/KL/2013/RR-20	Dr. Abdul Majeed K
10	Gauhati Medical College and Hospital, Department of Haematology, 3rd floor, old Buliding, Bhangagarh, Guwahati, Assam -781032, India	Institutional Ethics Committee GMCH, 2nd Floor, GMC Main Building, Narakasur Hilltop, Guwahati-781032, Assam, India ECR/1470/Inst/AS/2020	Dr. Damodar Das

11	HOCC Haemato Oncology Care Centre, Kedar, New India Mill compound, Behind Swadia Patel Hospital, Jetalpur Road, Vadodara, Gujarat -390020, India	Parikh Institutional Ethics Committee Parikh Multispecialty Health Care Pvt Ltd A 4 Bhagvati Park Society, Opposite Tube Company Near Apollo Clinic, Old Padra Road, Vadodara, Gujarat-390020 ECR/1734/Inst/GJ/2022	Dr. Seema Bhatwadekar
12	Arihant Multispeciality Hospital, Baidyanath Square, opposite capitol heights, opposite VR Mall, Nagpur-440026, Maharashtra, India	Rughwani Child Care Center and Hospital Institutional Ethics Committee, 22, Sindhu Nagar, Mohanlal Rughwani Marg, Jaripatka, Nagpur, 440014, Maharashtra, India ECR/1444/Inst/MH/2020	Dr. Dipty Jain
